Helene F E Gleitz
Overview
Explore the profile of Helene F E Gleitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fuchs S, Stalmann U, Snoeren I, Bindels E, Schmitz S, Banjanin B, et al.
Blood Adv
. 2023 Dec;
8(3):766-779.
PMID: 38147624
It is still not fully understood how genetic haploinsufficiency in del(5q) myelodysplastic syndrome (MDS) contributes to malignant transformation of hematopoietic stem cells. We asked how compound haploinsufficiency for Csnk1a1 and...
2.
Pritchard J, Pearce J, Snoeren I, Fuchs S, Gotz K, Peisker F, et al.
Cell Rep
. 2023 Dec;
43(1):113608.
PMID: 38117649
The role of hematopoietic Hedgehog signaling in myeloproliferative neoplasms (MPNs) remains incompletely understood despite data suggesting that Hedgehog (Hh) pathway inhibitors have therapeutic activity in patients. We aim to systematically...
3.
Ellison S, Liao A, Gleitz H, Parker H, Booth L, Robinson J, et al.
Mol Ther Methods Clin Dev
. 2023 Nov;
31:101127.
PMID: 37920237
Mucopolysaccharidosis type II (MPSII) is a pediatric lysosomal storage disease caused by deficiencies in the IDS (iduronate-2-sulfatase) gene resulting in accumulation of glycosaminoglycans, multisystem disease, and profound neurodegeneration in severe...
4.
Mascarenhas J, Gleitz H, Chifotides H, Harrison C, Verstovsek S, Vannucchi A, et al.
Leukemia
. 2022 Nov;
37(2):255-264.
PMID: 36434065
Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and clinical heterogeneity. At the two ends of the disease spectrum are the myelodepletive or cytopenic phenotype and the myeloproliferative...
5.
Gleitz H, Schneider R
Haematologica
. 2022 Aug;
108(5):1203-1204.
PMID: 36005565
No abstract available.
6.
Gleitz H, Pritchard J, Kramann R, Schneider R
Hemasphere
. 2022 Mar;
3(Suppl).
PMID: 35309783
No abstract available.
7.
Stalmann U, Ticconi F, Snoeren I, Li R, Gleitz H, Cowley G, et al.
Blood Adv
. 2022 Jan;
6(6):1780-1796.
PMID: 35016204
How genetic haploinsufficiency contributes to the clonal dominance of hematopoietic stem cells (HSCs) in del(5q) myelodysplastic syndrome (MDS) remains unresolved. Using a genetic barcoding strategy, we performed a systematic comparison...
8.
Gleitz H, Benabid A, Schneider R
Curr Opin Hematol
. 2021 Jul;
28(5):364-371.
PMID: 34232140
Purpose Of Review: Bone marrow fibrosis is the progressive replacement of blood-forming cells by reticulin fibres, caused by the acquisition of somatic mutations in hematopoietic stem cells. The molecular and...
9.
Gleitz H, Snoeren I, Fuchs S, Leimkuhler N, Schneider R
STAR Protoc
. 2021 May;
2(2):100538.
PMID: 34027494
Bone marrow (BM) mesenchymal stromal cells play an important role in regulating stem cell quiescence and homeostasis; they are also key contributors to various hematological malignancies. However, human bone marrow...
10.
Leimkuhler N, Gleitz H, Ronghui L, Snoeren I, Fuchs S, Nagai J, et al.
Cell Stem Cell
. 2020 Dec;
28(4):637-652.e8.
PMID: 33301706
Functional contributions of individual cellular components of the bone-marrow microenvironment to myelofibrosis (MF) in patients with myeloproliferative neoplasms (MPNs) are incompletely understood. We aimed to generate a comprehensive map of...